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Background: The European Union acknowledges the relevance of registries as key instruments for developing rare
disease (RD) clinical research, improving patient care and health service (HS) planning and funded the EPIRARE
project to improve standardization and data comparability among patient registries and to support new registries
and data collections.
Methods: A reference list of patient registry-based indicators has been prepared building on the work of previous
EU projects and on the platform stakeholders’ information needs resulting from the EPIRARE surveys and
consultations. The variables necessary to compute these indicators have been analysed for their scope and use and
then organized in data domains.
Results: The reference indicators span from disease surveillance, to socio-economic burden, HS monitoring,
research and product development, policy equity and effectiveness. The variables necessary to compute these
reference indicators have been selected and, with the exception of more sophisticated indicators for research
and clinical care quality, they can be collected as data elements common (CDE) to all rare diseases. They have
been organized in data domains characterized by their contents and main goal and a limited set of
mandatory data elements has been defined, which allows case notification independently of the physician or
the health service.
Conclusions: The definition of a set of CDE for the European platform for RD patient registration is the first
step in the promotion of the use of common tools for the collection of comparable data. The proposed
organization of the CDE contributes to the completeness of case ascertainment, with the possible
involvement of patients and patient associations in the registration process.
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The European Union (EU) acknowledges the rele-
vance of registries as key instruments for developing
rare disease (RD) clinical research, improving patient
care and health service (HS) planning [1,2]. The
European Commission has funded the EPIRARE and
other projects on EU patient registration, and stated
that its strategic objective is the creation of the
European Platform for RD patient registration (RDR),* Correspondence: domenica.taruscio@iss.it
1National Centre for Rare Diseases, National Institute of Health, Rome, Italy
Full list of author information is available at the end of the article
© 2014 Taruscio et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.providing common services and tools for the existing
(and future) rare disease registries in the EU [3]. The
EPIRARE project (“Building Consensus and Synergies
for the EU Registration of Rare Disease Patients”,
www.epirare.eu), studied a model for this platform [4]
and concluded that it should have an important role
in improving standardization and data comparability
and, where useful, supporting the set up of new regis-
tries. Actual data collection should be limited to
diseases for which disease-specific registries are not
sustainable or for which there is no specific research
interest. This article presents the results of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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elements (CDE) for the European RDR Platform.
Although European or wider data sharing would be
desirable to increase the power of data analyses, the
reference to the European RDR Platform CDE by new
and existing registries will impact positively on data
and indicator comparability independently of data
sharing, which might be dramatically hampered by
the next regulation on personal data protection,
which is currently under discussion in the EU
Parliament.
Methods
In line with recommended methodologies [5], at first a
reference list of registry-based indicators was defined,
starting from the indicators identified by the EUROPLAN
project [6] and the EU Rare Disease Task Force (RDTF)
[7]; some indicators were slightly modified or added, in
consideration of the opinions expressed by the RDTF
experts and of the information needs of the identified
stakeholders as resulting from the surveys [8,9] and con-
sultations [4] carried out during the EPIRARE activities.
The experts who reviewed the cited RDTF document and
the EUROPLAN Working Group on indicators are re-
ported in the cited documents. The process of selection of
the addressees of the EPIRARE surveys and consultations
is reported in the cited references. More detailed indica-
tions of the respondents and the EPIRARE advisory board
members are presented, respectively, in the deliverables
and partners sections of the EPIRARE project website
(www.epirare.eu). The resulting set of variables necessary
for the computation of these indicators was compared
with the information regarding institutional initiatives for
national RD registries already established or in preparation
which were notified to EPIRARE from experts in Belgium,
Bulgaria, France, Germany, Italy and Spain in order to
have the highest consistency among EU registries. The
definitions and formats of the selected variables were kept
as far as possible similar to the data elements used in the
US NIH Global Rare Disease Registry to facilitate any pos-
sible collaborative work. Finally, the peculiarities of some
variables and of their collection were also considered to
elaborate the proposed organization of the CDE set.
Results and discussion
The set of reference indicators
The set of rare disease indicators, which were used in this
study as reference for the selection of the CDE, is reported
in “Additional file 1”. These indicators span from disease
surveillance, to socio-economic burden, HS monitoring,
research and product development, policy equity and ef-
fectiveness. The indicators mentioned in the research area
have generic definitions, but represent many possible indi-
cators which may be defined for specific goals, mostlydepending on clinical data. “Additional file 1” reports also
the variables which were considered necessary for the
computation of each indicator.Specific features of groups of variables
Besides the computation of sound platform indicators
and other information outputs, some variables have a
particular importance for the best use of registry data.
These comprise a) an unambiguous universal patient
coding; b) the variables allowing indicator analysis by
diagnosis, geographic location of the patient and health
care services used by the patient; and c) variables allo-
wing the ethical processing of patient data, including
his/her willingness to participate in research.The set of common data elements and its organization
Following the results of the analysis described above and
in line with the cluster analysis of the scope of data collec-
tion by registries with different aims (Santoro M, Coi A,
Lipucci Di Paola M, Gainotti S, Mollo E, Taruscio D,
Vittozzi L, Bianchi F: A classification of the Rare Disease
Patient Registries aimed at identifying different infor-
mative needs, submitted), the data elements were orga-
nized in three different domains (Table 1). The first
domain aims mainly at facilitating the completeness of
case notification and includes the case identification, the
geographical location of the patient and of the services in-
volved in the patient treatment, as well as information on
the patient position regarding his/her participation in
research. This is the minimum information necessary to
characterize the case and most of it is collected in usual
medical practice; therefore, it is proposed as the man-
datory set of data elements. It is made of data which are in
the knowledge of the patient (or their family) and which
can be entered without the involvement of physicians or
the health services which follow the patient. Although
validation of patient-reported data may be recommended
before its inclusion in the database, this additional source,
by promoting the case notification to registry holders,
may increase the sensitivity of the registration system and
allow also sensitivity estimates. Finally, this data set pro-
vides information on the patient distribution and problem
dimension, and is of use for HS and clinical trial planning,
for the prioritization of product development and for
patient advocacy. The variables necessary to compute a
univocal patient code (EU GUID) have been selected fol-
lowing the results of Johnson et al. [10]. However, to im-
prove coding accuracy in a global context with multiple
languages and alphabets, it is considered necessary that
EU registry sources collect two additional elements for the
EU GUID elaboration: the country of birth, which is
already collected in the US-GRDR [11], and the national
unique identification code.
Table 1 The EPIRARE set of common data elements for the European RDR platform
COMMON DATA ELEMENTS collected
in the EPIRARE platform (elements in
bold require longitudinal data
collection)




Domain 1) Case characterization essentials
Case notification -
Mandatory data
EU Global Unique Identifier (EU GUID) This code is elaborated from the
following data elements:
Unambiguous patient coding (to be
processed according to legal provisions)
is necessary to keep the integrity of the
database and avoid duplication of
records.
• Patient given name: DEFINITION: “First
name of patient as recorded in birth
certificate, passport or identity card”;
FORMAT: full name, not initials
• Patient family name (at birth):
DEFINITION: “Family name of patient as
recorded in birth certificate, passport or
identity card”; FORMAT: full name, not
initials
The National Unique Identification Code
increases the accuracy of the EU GUID in
case of names in foreign languages. It
could be an optional part of the
encrypted code.
• Patient sex: see definition below
• Patient date of birth: see definition
below
• Patient city of birth: see definition
below
National Unique Identification Code
Patient sex DEFINITION: “Patient’s physical sex at
birth”; PERMISSIBLE VALUES: male,
female, other (in any format)
Allows studies of sex-related differences
in the disease epidemiology and clinical
features
Patient date of birth DEFINITION: “Date of patient’s birth
recorded in birth certificate, passport or
identity card”; FORMAT: complete date
(year, month, day) in any format
Allows studies of age-related disease
features.
For privacy reasons, depending on the
time course of the disease, this data is to
be communicated to the platform at the
appropriate level of precision (only
month and year or complete)
Patient city of birth DEFINITION: “Name of city/town/village
where the patient was born as it
appears on the birth certificate, passport
or identity card”; FORMAT: full name of
city.
This data may be communicated to the
platform only for some specific diseases
for studies of health determinants.
For privacy reasons, this data is to be
communicated to the platform with the
appropriate level of precision (e.g.
mapped to the province, or to postal
code). Moreover, it is important that
geographical names are mapped to the
INSPIRE identifiers [12]. This will enable
the link with platforms organized around
environmental spatial information, such
as environmental pollution databases.
This may offer an additional opportunity
to indicate the place with an
appropriate granularity to comply with
privacy needs.
Patient country of birth DEFINITION: “Name of country where
the patient was born as it appears on
the birth certificate, passport or identity
card”; FORMAT: full name of country
Increases the discriminatory power of
the EU GUID in global registries
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Table 1 The EPIRARE set of common data elements for the European RDR platform (Continued)
Diagnosis Multiple coding according to current
relevant classification systems is
recommended while waiting for a
general reference classification of rare
diseases
Attribution of a disease to the case
Patient city of residence DEFINITION: “Name of city/town where
the patient usually lives”; FORMAT: full
name of city
Attribution of the case to a geographic
area; prevalence, incidence, mobility
For privacy reasons, this data is to be
communicated to the platform with the
appropriate level of precision (e.g.
mapped to the province, or to postal
code). Moreover, it is important that
geographical names are mapped to the
INSPIRE identifiers [12]. This will enable
the link with platforms organized around
environmental spatial information, such
as environmental pollution databases.
This may offer an additional opportunity
to indicate the place with an
appropriate granularity to comply with
privacy needs.
Patient country of residence DEFINITION: “Name of country where
the patient usually lives”; FORMAT: full
name of country
Attribution of the case to a geographic
area; prevalence, incidence, mobility
ID Treatment Centre Treating Centre Full name/code; contact
data are optional to improve
identification
Attribution of the case to the treating
setting
Treating Centre City-Town FORMAT: full name of city Attribution of the centre to a
geographic area; patient mobility for
treatment; planning research/clinical
trials
It is important that geographical names
are mapped to the INSPIRE identifiers
[12].
Current and past participation in
clinical trials
Yes/No Planning research/clinical trials
Patient willingness to be contacted to
participate in a future clinical trial
Yes/No Planning research/clinical trials
Patient willingness to be contacted
about donating biological samples
Yes/No Planning research/clinical trials
Patient consent based on graduated consent forms
Patient contact contact details; preferred means of
contact (including via intermediary
physician); language
Domain 2) Determinants and services
Case characterization Other cases in the family Yes/No (If Yes: degree of kinship) Socio-economic burden of disease
Healthy carriers in the family Yes/No (If Yes: degree of kinship)
Case parents are consanguineous Yes/no Contribution of consanguinity
Genetic features of the patient Gene-HGNC Gene Symbol Link to genetic research platforms;
patient cohort selection
Chromosome number
Nucleotide sequence analyzed and
reference sequence systems with
accession and version number
Variant description in HGVS format
Variant description in other formats
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Table 1 The EPIRARE set of common data elements for the European RDR platform (Continued)
History of diagnosis Date of first symptoms onset DEFINITION: “Date when patient first
began experiencing symptoms or signs
of the rare disease”; FORMAT: complete
date (year, month, day) in any format
Age at onset; time to diagnosis
Date of first contact of patient with the
public Health Service
Date of the first time the patient
requested a medical visit of the health
service with reference to the symptoms
of the diagnosed rare disease
Time to diagnosis
ID Centre/physician referring the patient
to the RD centre
Centre/Physician Full name/code;
contact data are optional to improve
identification
Integration of RD centres in the general
Health Service
Date of current diagnosis DEFINITION: “Date when the current rare
disease diagnosis was made” FORMAT:
complete date (year, month, day) in any
format
Time to diagnosis; life expectancy at
diagnosis
Status of current diagnosis Suspected-confirmed Diagnostic patterns; time to diagnosis;
life expectancy at diagnosis
Methods used for current diagnosis List to be defined Diagnostic patterns
ID Centre which made diagnosis Centre Full name/code; contact data are
optional to improve identification
Centre which made diagnosis City-Town FORMAT: full name of city Patient migration for diagnosis
It is important that geographical names
are mapped to the INSPIRE identifiers
[12].
Patient referred after positive neonatal
screening result
Yes/no Sensitivity of neonatal screening tests;




Current orphan drug treatment DEFINITION: “A list of all current orphan
drugs that a patient is currently taking”;
FORMAT: name of all active ingredients
(ORPHANET list)
Current off-label drug treatment DEFINITION: “A list of all current drugs
(different from orphan drugs) that a
patient is currently taking”; FORMAT:
name of active ingredients
Current drug treatment DEFINITION: “A list of all current drugs
(different from orphan drugs) that a
patient is currently taking”; FORMAT:
name of active ingredients
Hospitalizations DEFINITION: “Cumulative number of
patient’s admissions to the hospital due
to the rare disease”; FORMAT: number
Transplantations Yes/No (If yes: date of transplantation;
tranplant material)
Surgeries Yes/No (If yes: date of surgery; ID code
of Surgery)
Current dietary regimens prescribed
as treatment
Yes/No (If yes: type of regimen)
Current assistive devices Yes/No (If Yes: Type of assistive devices
used by patient; ID Code of type of
device.
Other treatments If Yes: Type/Code of treatment; indicate
if current or date of administration
Biomaterial donated (Yes/no); If Yes: list to be defined
(e.g. Tissue or body fluid or other
specifications)
Planning research/clinical trials
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Table 1 The EPIRARE set of common data elements for the European RDR platform (Continued)
ID Biobank where the biological
sample is stored up
Biobank Full name/code; contact data
are optional to improve identification
Link to Biobanks; planning research/
clinical trials
(if the biobank storing the sample is
not known) ID Centre which sampled
the biomaterial
Sampling Centre Full name/code;
contact data are optional to improve
identification of the centre
Link to Biobanks; planning research/
clinical trials
Domain 3) Outcomes
Patient vital status (and date of death) Live/Dead (If Dead: complete date of
death (year, month, day) in any
formatRequired Sources: National Death
Registry or National Population Registry
Education level Values from 0 to 8, based on the ISCED
2011 classification
Studies of socio-economic burden.
Comparison and matching of patient
populations from different data sources
on the basis of socio-economic data.
Applicable to individuals from early
childhood.
Occupational status Self-defined current economic status






Studies of socio-economic burden.
Comparison and matching of patient
populations from different data sources
on the basis of socio-economic data.
Applicable to individuals more than 16
year old.
Patient HRQoL index score Patient health-related quality of life
(HRQoL) generic questionnaires with
calculation of QALYs or the utility score
assessment of the Health-related Quality
of Life; QALYs; equitable decision-
making
Comorbidity DEFINITION: “Other diseases observed in
the patient”; FORMAT: ICD10 (multiple
coding in case that other RD are
observed)
Remarkable or unusual symptoms Remarkable or unusual symptoms,
including adverse effects of treatments,
and their severity (based on a 5-degree
scale).
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aims at characterizing the patient risk factors and at
monitoring and planning the operation of the health
services. It extends the patient characterization with
genetic data and with data regarding his/her health sta-
tus and familial information. Moreover, this domain in-
cludes data regarding the history and status of diagnosis
and treatments. This information can be collected from
a variety of sources and requires specific methodological
expertise for the data collection and use for HS research.
The third domain aims at supporting outcome ana-
lysis. It includes data of patient death; of health-related
quality of life (HRQoL), education level attained and
occupational status for an integrated assessment of the
patient condition;, and of co-morbidity and other symp-
toms, which are observed and may be associated with
the case disease and treatments. The assessments of
the education level attained, occupational status and
HRQoL, which are not in the usual interest of pathology
registries, require the administration of a short question-
naire. These data are extremely important since many
RD are not impacting on the lifetime and can servemany purposes, from patient-centered description of the
disease course, to monitoring the impact of policies and
best practices, to provide a basis for patient advocacy
actions and to equity decisions based on the burden of
disease and on assessments cutting across all diseases.
The variety of disease specific clinical data and of their
observation conditions prevents, at present, its collection
within a set of CDE, although they are central in the
interest of clinicians and in the scope of many registries.
The EPIRARE project suggested that the European RDR
Platform could host a section of metadata of the clinical
observations collected by individual registries, in order
to facilitate traceability of existing data and contacts with
registries collecting relevant data.
Conclusions
The definition of a set of CDE for the European RDR Plat-
form has different bearings for the databases of registries
in comparison to the database in the European RDR Plat-
form. For registries, this set of CDE is not to be consid-
ered as the fixed structure of a common database to be
used by all registries regardless of their purposes. Rather,
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of registries for a variety of purposes. Therefore a registry
should select, beside the mandatory set (domain 1 data),
the data elements, which are necessary to compute the in-
dicators relevant for the purposes it intends to pursue,
and collect the corresponding data according to the defi-
nitions and formats proposed. Moreover, in case that the
registry intends to collect outcome data, it is recom-
mended that all the data indicated in domain 3 are col-
lected. Finally, it is up to the registry the choice to collect
additional data, not included in the set of CDE, for more
detailed or specialized observations which are necessary
for its own specific study purpose, such as treatment-
specific features or disease-specific clinical data. Therefore
the adoption of the European RDR Platform CDE has the
main aim to promote the collection, according to com-
mon specifications, of data necessary to compute indica-
tors which are both relevant to the purpose of the registry
and key for more general purposes regarding RD, the
achievement of which may require indicator and data
comparability. The actual practice of collection of this data
according to the specifications proposed by EPIRARE, the
feasibility of adaptation to the proposed specification and
the further usability of data already collected has been
studied and is the subject of a manuscript in preparation.
Moreover, this practice will contribute, in case that this
will be allowed by the next regulation on data protection,
to the interoperability and data merging among different
registries. Within a scenario of feasible data sharing, the
European RDR Platform could accommodate and use the
relevant data communicated by registries for the compu-
tation, as far as feasible, of indicator values from a wider
evidence base, or to support the collection of data tailored
to the specific features of many different diseases. For
these aims, its database should necessarily consist of the
full set of CDE and, likely, of additional metadata to facili-
tate traceability of existing data and contacts with the
sources of data, including more detailed or specific obser-
vations. The definition of a set of CDE for the European
RDR Platform is the first step in the promotion of the use
of common tools for the collection of comparable data of
RD patients. The next step in this process is the definition
of common references for those data which can be en-
tered following different coding systems, catalogues or
measuring scales. The standards and terminologies to be
used in the platform should be agreed with clinical and
epidemiological experts and, possibly, involving represen-
tatives of EU national information systems.
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